Article Text

Download PDFPDF
Severe hepatitis related to immune-checkpoint inhibitor in a patient with non-small-cell lung cancer and pulmonary tuberculosis
  1. Chuan-Yen Sun1,
  2. Chia-I Shen1,
  3. Jia-Yih Feng1,
  4. Chi-Lu Chiang1,2
  1. 1 Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  2. 2 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
  1. Correspondence to Chi-Lu Chiang, Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei, Taiwan;clchiang{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


A 72-year-old male heavy smoker was diagnosed with stage IV non-small-cell lung cancer (NSCLC) with lung-to-lung metastasis. No druggable driver mutation was found and the tumour proportion score for programmed death (PD)-ligand 1 expression was 100% (Dako 22C3 assay). The result of sputum acid-fast staining, performed 1 month after the diagnosis, was positive. After confirmation by PCR (DR. MTBC ScreenTM IVD Kit), isoniazid, rifampin, ethambutol and pyrazinamide were administered for pulmonary tuberculosis (TB). A viral hepatitis panel performed before the administration of the anti-TB agents was negative for hepatitis B virus and hepatitis C virus infections. The patient’s liver enzyme levels were within the normal ranges before anti-TB agents, during anti-TB treatment and before immune-checkpoint inhibitor (ICI) treatment. Pembrolizumab monotherapy was administered 1 month after the administration of the anti-TB agents and sputum conversion. Unfortunately, the …

View Full Text


  • Contributors Conception and design of study: CLC. Acquisition of data: CYS. Drafting the manuscript: CYS, CIS. Revising the manuscript critically for important intellectual content: JYF, CLC. Approval of the version of the manuscript to be published: All authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests CLC received honoraria from AstraZeneca, Boehringer Ingelheim, Roche and Merck Sharp & Dohme.

  • Patient consent for publication Consent obtained directly from patient(s).

  • Provenance and peer review Not commissioned; externally peer reviewed.